NASDAQ:MGRX Mangoceuticals Q2 2025 Earnings Report $0.45 +0.00 (+0.69%) As of 12:12 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Mangoceuticals EPS ResultsActual EPS-$0.57Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMangoceuticals Revenue ResultsActual Revenue$0.17 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMangoceuticals Announcement DetailsQuarterQ2 2025Date8/14/2025TimeAfter Market ClosesConference Call DateThursday, August 14, 2025Conference Call Time7:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Mangoceuticals Earnings HeadlinesCritical Analysis: Chemed (NYSE:CHE) and Mangoceuticals (NASDAQ:MGRX)September 23 at 5:13 AM | americanbankingnews.comMangoceuticals Terminates Planned Business Combination with NucleaAugust 21, 2026 | tipranks.comIran War TRUTH: What Two Congressmen Led Me ToTwo private meetings with U.S. Congressmen on March 2nd, three days after the first missiles fell, sent one analyst down an unexpected research trail. The investigation uncovered a coordinated operation, a shadow group running it, and one company sitting at the center of it all.September 24 at 1:00 AM | Behind the Markets (Ad)MGRX Stock Alert: Halper Sadeh LLC is Investigating Whether Mangoceuticals, Inc. is Obtaining a Fair Price for its ShareholdersAugust 17, 2026 | businesswire.comMangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology AssetsAugust 13, 2026 | markets.businessinsider.comMangoceuticals Inc.'s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology AssetsAugust 13, 2026 | globenewswire.comSee More Mangoceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mangoceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mangoceuticals and other key companies, straight to your email. Email Address About MangoceuticalsMangoceuticals (NASDAQ:MGRX) is a telehealth company focused on men’s health and wellness. Operating under the MangoRx brand, the company provides an online platform through which eligible customers can complete a medical consultation with a licensed provider and, when appropriate, receive prescription treatments delivered directly to their homes. The company’s offerings are centered primarily on erectile dysfunction, hair loss and related men’s wellness needs. Its product portfolio has included branded treatments such as MANGO ED, as well as therapies for hair growth and other conditions. Treatments are prescribed following an online evaluation and may be fulfilled through partner or compounding pharmacies, subject to applicable medical and regulatory requirements. Mangoceuticals serves customers in the United States through its direct-to-consumer digital platform. The company was established to combine telemedicine, prescription fulfillment and consumer-focused branding in the men’s healthcare market. Available public information about its broader geographic expansion and leadership is limited.View Mangoceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI Infrastructure Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
